Accessibility Menu
Merck logo

Merck(NYSE) MRK

Market Cap$335.14BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1968)+66,327%
5 Year+107%
1 Year+70%
1 Month+10%
$136.01
+0.13%
+0.17Today
Merck last closing stock price
MetricPriceDate
Last closeUSD 135.842026-08-14
Merck stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.65%USD 128.582026-08-07
1 month+9.89%USD 123.612026-07-15
3 month+22.84%USD 110.582026-05-15
Year to date+30.94%USD 103.742025-12-31
1 year+69.62%USD 80.082025-08-14
3 year+37.11%USD 99.072023-08-15
5 year+106.95%USD 65.642021-08-13
Since inception+66,327%USD 0.201968-01-02

Merck Financials at a Glance

Market Cap

$335.14BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$66.40B

Net Income (TTM)

$3.17B

EPS (TTM)

$1.25

P/E Ratio

108.58

Dividend

$3.36

Beta (Volatility)

0.27 (Low)

Price

$136.01

Volume

4,617,710.43

Open

$134.95

Previous Close

$135.84

Daily Range

$134.55 - $137.17

52-Week Range

$77.58 - $137.17

Estimated Earnings Date

Oct 29, 2026

MRK News

Two scientists looking at a monitor showing brain scans.

4 Best Cancer Stocks for 2026 and How to Invest

Keith SpeightsAug 16, 2026
GettyImages-941740978-1201x801-d21b45d

The Largest Healthcare Companies by Market Cap in August 2026

Lyle DalyAug 6, 2026
office_building_commercial_real_estate

5 Best Commercial Real Estate Stocks for 2026

Kristi WaterworthJul 16, 2026
Two people looking at a chart.

5 Best High Dividend Mutual Funds to Buy in 2026

Matt DiLalloJul 14, 2026
Doctor giving patient a vaccine shot.

6 Best Vaccine Stocks for 2026 and How to Invest

Keith SpeightsJul 13, 2026
Pharmacists reviewing medication

5 Best GLP-1 Stocks for 2026 and How to Invest

Rachel WarrenJun 24, 2026
maxresdefault (2)

Merck: Navigating the Patent Cliff and Future Growth Prospects

Motley Fool YouTubeJun 4, 2026
The word Index against a background of colored stripes

Dow Jones Industrial Average

Jeremy BowmanMay 16, 2026
Page 1

MRK: Motley Fool Moneyball Superscore

77

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Merck

Merck & Co., Inc. operates as a global healthcare company with a strong focus on pharmaceutical and vaccine innovation. The company is recognized for its significant contributions to the field of oncology, as well as its diversified product portfolio, which includes a range of vaccines, biologic therapies, and animal health products.

Products and Services

Pharmaceuticals: Notable for their blockbuster drug Keytruda, used in cancer treatment.

Vaccines: Providing immunization solutions including those for HPV and rotavirus.

Anesthesia and analgesia: Supplying medications for pain relief and sedation.

Animal Health: Offering veterinary pharmaceuticals and vaccines.

What Makes Merck & Co., Inc. Special

Merck & Co., Inc. distinguishes itself through its robust pipeline of innovative products across multiple therapeutic areas. Their focus on oncology, vaccines, and rare diseases, alongside a strategic approach to research and development, supports its competitive advantage. Additionally, the company’s operational efficiency and strategic global market expansions contribute to its resilience and growth potential.

Five Things You Need to Know

Keytruda is a leading cancer treatment driving the company's revenue growth.

The company has a strong pipeline with 20 potential growth drivers.

Merck maintains substantial gross margins which support reinvestment and cash flow.

The company is expanding into international markets like China and Europe.

Potential challenges include patent expirations and biosimilar competition.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

75,000

CEO

Robert M. Davis, MBA

Website

www.merck.com

Headquarters

Rahway, NJ 07065, US

MRK Financials

Key Financial Metrics (TTM)

Gross Margin

75.38%

Operating Margin

16.65%

Net Income Margin

4.78%

Return on Equity

6.60%

Return on Capital

22.77%

Return on Assets

2.44%

Earnings Yield

0.92%

Dividend Yield

2.47%

Payout Ratio

2.62%

Stock Overview

Market Cap

$335.14BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.47B

Volume

4.62M

Avg. Volume

10.20M

Financials (TTM)

Gross Profit

$50.05B

Operating Income

$11.06B

EBITDA

$13.84B

Operating Cash Flow

$19.97B

Capital Expenditure

-$3.90B

Free Cash Flow

$16.06B

Cash & ST Invst.

$7.14B

Total Debt

$53.91B

Merck Performance Analysis

Merck annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 58,473,000,00019.6%
20232023-12-31USD 59,871,000,0002.4%
20242024-12-31USD 63,973,000,0006.9%
20252025-12-31USD 64,926,000,0001.5%
Merck sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-308.8%
Q42025-12-31-5.0%
Q12026-03-31-0.2%
Q22026-06-302.0%
Merck annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 5.7111.1%
20232023-12-31USD 0.14-97.5%
20242024-12-31USD 6.744600.8%
20252025-12-31USD 7.288.1%
Merck sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3031.8%
Q42025-12-31-48.7%
Q12026-03-31-244.5%
Q22026-06-3068.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$16.61B

+5.1%

Gross Profit

$12.21B

+2.2%

Gross Margin

73.54%

N/A

Market Cap

$335.14BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.53M

N/A

Employees

74,000

N/A

Net Income

-$1.34B

-130.2%

EBITDA

$1.43B

-77.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$7.14B

-17.2%

Total Debt

$53.91B

+52.3%

Accounts Receivable

$12.56B

+6.1%

Inventory

$6.21B

-6.0%

Long Term Debt

$51.08B

+50.4%

Short Term Debt

$2.83B

+97.0%

Return on Assets

2.44%

N/A

Return on Invested Capital

10.83%

N/A

Free Cash Flow

$4.48B

+77.0%

Operating Cash Flow

$5.37B

+63.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NVSNovartis AG
$152.03+0.76%
AZNAstraZeneca PLC
$156.63+0.12%
AMGNAmgen Inc.
$418.37+0.76%
TMOThermo Fisher Scientific Inc.
$586.67-0.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64-0.01%
SPCXSpace Exploration Technologies
$145.49+0.04%
IPSTIp Strategy
$7.70+2.50%
NOKNokia
$10.84+0.01%

Questions About MRK

What is the current price of Merck?

Merck is trading at $135.74 per share.

What is the 52-week range for Merck?

Over the past 52 weeks, Merck has traded between $77.58 and $137.17.

How much debt does Merck have?

As of the most recent reporting period, Merck reported total debt of $53.91B.

How much cash does Merck have on hand?

Merck reported $6.89B in cash and cash equivalents in its most recent financial results.

What is Merck’s dividend yield?

Merck currently has a dividend yield of 2.47%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services